Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multidrug-resistant (MDR) bacterial infections.
Spero is committed to advancing innovative therapies for patients with rare diseases and serious MDR bacterial infections in both hospital and community settings. The company believes that embedding ESG considerations into its business strategies will not only drive sustained long-term value for its shareholders but also create a positive impact on the patients and communities it serves. As part of these considerations, the company is establishing and reviewing its policies with the aim of implementing new programs, if and when needed, to address pertinent ESG risks and opportunities, ensuring it maintains responsible and sustainable business practices.
Proxy Statement Disclosure:
Environmental, Social, and Governance
We are deeply committed to advancing new therapies for patients with rare orphan diseases and serious, multi-drug resistant bacterial infections in both hospital and community settings. Our dedication to developing our environmental, social, and governance (“ESG”) program is rooted in the belief that integrating environmental, social, and governance considerations into our business strategies will not only drive long-term value for our stockholders but also positively impact the patients and communities in which we operate. As part of our focus to evolve our ESG program, we are establishing and strengthening our policies and disclosures and implementing new programs to address relevant ESG risks and opportunities.
ESG Oversight
Our Board of Directors and executive leadership team take part in overseeing any ESG initiatives.
Environmental Management
We recognize that addressing our environmental impact is crucial for the well-being of future generations. We are dedicated to understanding and managing our environmental footprint effectively.
Human Capital Management
Our success as a company is significantly influenced by the dedication and expertise of our employees. We prioritize human capital management by fostering a culture of inclusivity, learning, and well-being. We strive to provide a safe and supportive work environment that values diversity, encourages professional development, and promotes work-life balance through flexible work hours in a hybrid environment. Through our learning and development platform, our employees have the opportunity to enroll in live classes on topics of their choosing. Additionally, we maintain open channels of communication to engage with our employees, gather feedback, and address their concerns.
Diversity and Inclusion
Diversity and inclusion are at the core of our values. We are committed to promoting a diverse workforce, where all employees feel respected, valued, and empowered to contribute to our mission. We are actively working to increase representation across all levels of our organization, including leadership roles. Through targeted initiatives, such as diversity, equity, and inclusion workshops, we aim to foster an inclusive workplace that celebrates individual differences and enables the exchange of diverse perspectives.
Quality and Safety
Ensuring the quality and safety of our operations is of utmost importance. We maintain stringent quality control processes and adhere to all relevant regulatory standards to guarantee the safety, efficacy, and reliability of our medicines. Patient safety is a top priority, and we continuously monitor and improve our quality management systems to develop and deliver treatments that patients and healthcare providers can trust.
Business Ethics
We uphold the highest standards of business ethics and integrity. Our commitment to ethical conduct is reflected in our Code of Business Conduct and Ethics, which outlines principles and guidelines for all employees, contractors, and partners to follow. We promote transparent and honest communication with stakeholders, safeguarding the trust they place in us.
Spero Therapeutics was founded in 2013 and went public on November 2, 2017.
Spero Therapeutics is listed on the NASDAQ Global Market with a ticker symbol of SPRO.
Spero Therapeutics is headquartered in Cambridge, MA.
You can find information about the Board of Directors and Leadership Team on our website, here.
We currently do not pay a dividend and do not offer a Dividend Reinvestment Plan.
84833T103.
You will need to open a brokerage account.
Please contact your broker if you own your shares through a broker, or if you beneficially own your shares, please contact our transfer agent.
Computershare is Spero's transfer agent.
Our legal counsel is Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Our independent auditor is PwC.
Spero Therapeutics is incorporated in Delaware, United States.
We do not yet have a comprehensive ESG reporting system. We recognize the importance of ESG and are actively working towards it.
You can reach out to investor relations at IR@sperotherapeutics.com.
To subscribe to Spero Therapeutics’ email list, sign up here.
All SEC filings can be found and downloaded here.
Spero Therapeutics is committed to advancing novel treatment approaches for rare diseases and MDR bacterial infections. Our experienced team of experts embrace the Latin word “spero,” which means “hope.” It is our mission to bring hope to patients and families of loved ones suffering from rare diseases and serious infections.
Spero Therapeutics is pursuing collaborations with partners for expertise and funding support.
Join our life-changing mission to deliver differentiated treatments to patients suffering with rare diseases and MDR bacterial infections. We seek individuals with unique talents who share our passion.
Have a question? Reach out to us!
